| backgroud Chronic or acute liver function failure disease is a majorhealth problem. It is widely prevalent in China (30 million individuals).Liver failure due to various reasons, hepatitis B virus infection remains amajor cause of morbidity and mortality. Clinically need treatment ofartificial liver support system (ALSS) or liver transplantation. However,transplantation is severely limited by the unpredictable and limitedavailability of organs, immunosuppressive complications, and long-termgraft failure. Therefore, the management of liver failure is receivinggreater attention. New and more efficient liver failure therapies areneeded, including those with the ultimate goal of restoring function byregenerating and repairing damaged hepatocyte.Stem-cell therapy offers the most promise in this regard, especiallyin light of recent advances in the understanding of stem-cell biology andtransplantation. Stem cells are defined as cells that are clonogenic(capable of producing exact duplicates), self-renewing (capable ofdividing indefinitely), and potent (capable of differentiating into multiplecell lineages). Bone marrow is composed of various types of cells of specificphenotypes and function. Bone marrow cells can be transplanted either astotal, unfractionated bone marrow or as a well-defined subpopulation ofBMSCs. BMSCs has recently gained attention as a potential source ofmultipotent stem cells for cell, particularly because of its relatively easyto obtain from autologous bone marrow, to expand in vitro withoutsacrificing multipotency, to cryopreserve for future use, and ability totransdifferentiate into hepatic-like cells (rodent and human) were shownto express hepatocyte-specific markers.Stem-cell therapy for ischemic heart failure is very promising. Initialanimal trials have provided good results. However, the major challengestill need to be resolved before stem-cell therapy can be introduced fullyinto clinical practice. These issues include defining the strategies that canbe used to drive stern cells to differentiate into specific hepatic cells invitro, for enriching and purifying specific cell type populations in vitro,developing large-scale culture techniques, determining the efficacy ofvarious transplantation techniques, and characterizing the properties ofstem-cell grafts in vivo.Objective To observe the homing capacity of bone mesenchymal stemcells(BMSCs) to rat with acute hepatic failure(AHF).Methods BMSCs were isolated from rat bone marrow with the methodof density gradient centrifugation and stick-to-wall screening, and the surface markers were identified with flow cytometry after amplificationin vitro. BMSCs were labeled with Bromodeoxyuridine(BrdU). AHFanimals were induced by D-galactosamine(D-gal). transplantation oflabeled BMSCs (1-1.5×10~6) were performed on the AHF rats(groupA)/normal rats(group C), another AHF group(group B) were injected withsodium chloride without BMSCs as a control to group A. Then themortality of the rats and liver function recovery status were observes.Two weeks after cells transplantation, BMSCs traced with BrdU weredetected in the livers by immunohistochemistry.Results The mortality and status of liver function were notsignificantly different between A and B group. Both A and C group couldfind BrdU~+ cells and the number and the disposition of BrdU~+ cells in Agroup was much more than C group's, showing significant difference.Conclusion BMSCs have capacity of homing to the liver of rat innormal or in injury. But the number of BMSCs homing to liver might berelated to the extent of liver injury. |
PDF Full Text Request